Search

Your search keyword '"Gudrun Wallenstein"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Gudrun Wallenstein" Remove constraint Author: "Gudrun Wallenstein"
18 results on '"Gudrun Wallenstein"'

Search Results

1. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?

2. Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men

Catalog

Books, media, physical & digital resources

3. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study

4. Strategic and Statistical Considerations on the QT Assessment of Volasertib

5. Efficacy and Safety Results of the Afatinib Expanded Access Program

6. What is an estimandhow does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?

7. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

8. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

9. Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men

10. Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials

11. [Untitled]

12. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

13. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease

14. Results of the Afatinib Expanded Access Program (EAP): Efficacy and Safety

15. Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study

16. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy

17. A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM)

18. Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers.